Novo Nordisk announced on Monday the launch of the first oral GLP-1 pill for obesity treatment in the United States, marking a major shift in weight-loss care. The daily pill, called Wegovy Pill, is priced between $149 and $299 per month depending on dosage, significantly undercutting the cost of weekly injections.
The launch comes just two weeks after U.S. regulatory approval. The starting dose is now available at more than 70,000 pharmacies nationwide, with higher doses rolling out by the end of the week. Novo Nordisk said the pill could expand treatment options for more than 100 million Americans living with obesity and open a new phase in the fast-growing GLP-1 market.
